← Back to headlines
Avalyn Surges on Public Debut
Lung disease drug developer Avalyn Pharmaceuticals saw its stock surge following its public debut, indicating strong investor interest.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
